There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zogenix (ZGNX), Puma Biotechnology (PBYI) and Homology Medicines (FIXX) with bullish sentiments.
Puma Biotechnology (PBYI)
H.C. Wainwright analyst Edward White maintained a Buy rating on Puma Biotechnology today and set a price target of $15.00. The company’s shares closed last Friday at $10.83.
According to TipRanks.com, White is a top 100 analyst with an average return of 40.6% and a 56.9% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Aeglea Biotherapeutics.
Puma Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.
Homology Medicines (FIXX)
In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Homology Medicines, with a price target of $30.00. The company’s shares closed last Friday at $10.23, close to its 52-week low of $8.70.
According to TipRanks.com, Trucchio is a 3-star analyst with an average return of 7.2% and a 52.8% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Flexion Therapeutics, and Vir Biotechnology.
Homology Medicines has an analyst consensus of Strong Buy, with a price target consensus of $29.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FIXX:
